Evidence map›Paper›PMID 26335242›Full record

ArticleInternational journal of clinical oncology2016

Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.

Gui-Ming Zhang, Yao Zhu, Wei-Jie Gu, Hai-Liang Zhang, Guo-Hai Shi, Ding-Wei Ye

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gui-Ming ZhangDepartment of Urology, Fudan University, Shanghai Cancer Center, No. 270, Dong'an Rd, Shanghai, 200032, People's Republic of China.
Yao ZhuDepartment of Urology, Fudan University, Shanghai Cancer Center, No. 270, Dong'an Rd, Shanghai, 200032, People's Republic of China.
Wei-Jie GuDepartment of Urology, Fudan University, Shanghai Cancer Center, No. 270, Dong'an Rd, Shanghai, 200032, People's Republic of China.
Hai-Liang ZhangDepartment of Urology, Fudan University, Shanghai Cancer Center, No. 270, Dong'an Rd, Shanghai, 200032, People's Republic of China.
Guo-Hai ShiDepartment of Urology, Fudan University, Shanghai Cancer Center, No. 270, Dong'an Rd, Shanghai, 200032, People's Republic of China.
Ding-Wei YeDepartment of Urology, Fudan University, Shanghai Cancer Center, No. 270, Dong'an Rd, Shanghai, 200032, People's Republic of China. yedingwei1963@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcomes of various cancers. This study aimed to evaluate whether pretreatment NLR can be used as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapy.

methodsIn this single-center retrospective study, the Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) of 373 mRCC patients receiving targeted therapy. The survival outcomes of patients with high (≥ 2.2) and low (< 2.2) pretreatment NLRs were compared by log-rank test, and Cox proportional hazard regression model was used to compare OS and PFS between groups.

resultsThe overall median PFS and OS times for all 373 patients were 18.4 and 34.3 months, respectively. Patients with high NLRs had significantly shorter median OS (28.8 vs 410 months, P = 0.005) and PFS (15.4 vs 23.9 months, P = 0.001) than those with low NLRs. After adjusting for confounding variables, each unit increase of NLR was associated with a 40 % increase in mortality (hazard ratio [HR] 1.391; 95 % confidence interval [CI] 1.022-1.894; P = 0.036). High NLR was also an independent predictor of poor PFS (HR 1.544; 95 % CI 1.166-2.045; P = 0.002).

conclusionPretreatment NLR may be an independent prognostic factor for mRCC patients who are receiving targeted therapy.

Indexed as

Molecular Targeted TherapyAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Renal CellFemaleHumansKidney NeoplasmsLymphocytesMaleMiddle AgedNeoplasm ProteinsNeutrophilsPrognosisAntineoplastic AgentsNeoplasm ProteinsMetastasisNeutrophil-to-lymphocyte ratioPrognosisRenal cell carcinomaTargeted therapy

Identifiers

PMID26335242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.